Temperature-controlled radiofrequency neurolysis of posterior nasal nerve benefits patients with chronic rhinitis

Results

The mean pretreatment rTNSS was 7.8 (95% CI, 7.5–8.1). The significant rTNSS treatment effect at 3 months (−4.2 [95% CI, −4.6 to −3.8]; p < 0.001) was sustained through 2 years (−4.5 [95% CI, −5.0 to −3.9]; p < 0.001), a 57.7% improvement. At 2 years, the proportion of patients with a minimal clinically important difference (MCID) of ≥30% improvement in rTNSS from baseline was 80.0% (95% CI, 71.4%–86.5%). Individual postnasal drip and cough symptom scores were significantly improved from baseline through 2 years. The proportion of patients who reached the MCID for the MiniRQLQ (≥0.4-point improvement) at 2 years was 77.4% (95% CI, 68.5%–84.3%). Of 81 patients using chronic rhinitis medications at baseline, 61.7% either stopped all medication use (28.4%) or stopped or decreased (33.3%) use of ≥1 medication class at 2 years. No device/procedure-related serious adverse events were reported throughout 2 years.

TCRF neurolysis of the PNN resulted in sustained improvements in chronic rhinitis symptom burden and quality of life through 2 years, accompanied by a substantial decrease in medication burden.

Reference:

Lee, J.T., Abbas, G.M., Charous, D.D., Cuevas, M., Göktas, Ö., Loftus, P.A., Nachlas, N.E., Toskala, E.M., Watkins, J.P. and Brehmer, D. (2023), Two-Year Outcomes After Radiofrequency Neurolysis of Posterior Nasal Nerve in Chronic Rhinitis. The Laryngoscope. https://doi.org/10.1002/lary.31120

Keywords:

Temperature-controlled, radiofrequency, neurolysis, posterior, nasal, nerve, benefits, patients, chronic rhinitis, Lee, J.T., Abbas, G.M., Charous, D.D., Cuevas, M., Göktas, Ö., Loftus, P.A., Nachlas, N.E., Toskala, E.M., Watkins, J.P. and Brehmer, D, Laryngoscope